bluebirdbio.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
# robots.txt for https://www.bluebirdbio.com User-Agent: * Sitemap: | ||
Meta Tags
| Title | bluebird bio | Pioneering Gene Therapies | Recode for |
| Description | Setting the standard for gene About Us Our Leadership Diversity, Equity & Inclusion Collaborations Compliance & Ethics Corporate Giving Our Focus Beta-Thalassemia Cerebral Adrenoleukod |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 137.116.78.243 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
bluebirdbio.com Valuation
|
US$98,835,588
Last updated: 2023-04-27 08:05:12
bluebirdbio.com has Semrush global rank of 107,090. bluebirdbio.com has an estimated worth of US$ 98,835,588, based on its estimated Ads revenue. bluebirdbio.com receives approximately 11,404,107 unique visitors each day. Its web server is located in United States, with IP address 137.116.78.243. According to SiteAdvisor, bluebirdbio.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$98,835,588 |
| Daily Ads Revenue | US$91,233 |
| Monthly Ads Revenue | US$2,736,986 |
| Yearly Ads Revenue | US$32,843,826 |
| Daily Unique Visitors | 760,274 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| bluebirdbio.com. | A | 300 | IP: 137.116.78.243 |
| bluebirdbio.com. | A | 300 | IP: 104.40.250.100 |
| bluebirdbio.com. | NS | 300 | NS Record: nsusa.comlaude.net. |
| bluebirdbio.com. | NS | 300 | NS Record: nsgbr.comlaude.co.uk. |
| bluebirdbio.com. | NS | 300 | NS Record: nssui.comlaude.ch. |
| bluebirdbio.com. | MX | 3600 | MX Record: 10 us-smtp-inbound-2.mimecast.com. |
| bluebirdbio.com. | MX | 3600 | MX Record: 10 us-smtp-inbound-1.mimecast.com. |
| bluebirdbio.com. | TXT | 300 | TXT Record: v=spf1 include:_netblocks.mimecast.com include:sendgrid.net include:spf.mandrillapp.com include:amazonses.com include:spf.protection.outlook.com ~all |
| bluebirdbio.com. | TXT | 300 | TXT Record: MS=ms27130395 |
| bluebirdbio.com. | TXT | 300 | TXT Record: 60qvs25rrbs8ry59807h9hf906tr9tl2 |
| bluebirdbio.com. | TXT | 300 | TXT Record: apple-domain-verification=qziZgH3JMdX92bkc |
| bluebirdbio.com. | TXT | 300 | TXT Record: docusign=8ae144f8-b31e-4524-ad69-68d22cb55b05 |
| bluebirdbio.com. | TXT | 300 | TXT Record: docusign=b311653a-f018-4fe1-8cc3-96ae2aca99c9 |
| bluebirdbio.com. | TXT | 300 | TXT Record: mc-e3d0fc64-971b-45a4-843b-336720-cd.azurewebsites.net |
| bluebirdbio.com. | TXT | 300 | TXT Record: AC054B0EA3F263A6E805B6ABFFAB541F2B6D083A19233B9D710A7321CDC05287 |
| bluebirdbio.com. | TXT | 300 | TXT Record: BA47B9D829CAFA9A9643F1B3CCB3BB07717C036E46F84DA6085A58B860AB9A6B |
| bluebirdbio.com. | TXT | 300 | TXT Record: google-site-verification=7pDTQMinU-xXsHzd__7a0Xffh5RqqOP8ag96hPRBQcs |
| bluebirdbio.com. | TXT | 300 | TXT Record: google-site-verification=X_m-CT7ZcNgKldEdajT1GVqoM32SpAvOS7wm0V_u3Gk |
| bluebirdbio.com. | TXT | 300 | TXT Record: google-site-verification=qKk9YrJvOSGaMUMlrQSKGizYpbeANPqSwF4ikVFgeKo |
| bluebirdbio.com. | TXT | 300 | TXT Record: fg8p4ZNcqXGbDBVNawYxkgcoH3yKkuJo9MlGTn8C6gwVfAsauq1jo6BBtNObgAR3OfHK32n/EPsaFa7Wx8wGzQ== |
| bluebirdbio.com. | TXT | 300 | TXT Record: atlassian-domain-verification=ZVFyGLhUjBVW3roDCzxftBWrTsXSaL7J/FYAhmdrrYbmouRqmATQNCowoy0bn1ho |
| bluebirdbio.com. | TXT | 300 | TXT Record: atlassian-domain-verification=kz9XK5x4ApRU7M2coAu8a6pYzl8Qaojy1ikaQ1yBcZZZqsTpYAIJ5p9ygI4XZZEj |
HtmlToTextCheckTime:2023-04-27 08:05:12
| About Us Our Leadership Diversity, Equity & Inclusion Collaborations Compliance & Ethics Corporate Giving Our Focus Beta-Thalassemia Cerebral Adrenoleukodystrophy Sickle Cell Disease Our Science Our Approach to Gene Therapy Our Treatment Process Our Pipeline Clinical Trials Our Therapies Patients & Advocacy Patient Advocacy Patient Resources Access Policy Investors & Media Contact Us Careers We’re pursuing curative gene therapies to give patients and their families more bluebird days. Novel treatment option approved for CALD bluebird announces first FDA approved therapy for rare, neurodegenerative condition Read More We Persist for Patients Your reality shapes our actions & intentions Learn More Meet our leadership We’re probably biased, but these are some great minds. Get introduced You are now leaving www.bluebirdbio.com to go to another bluebird bio site. Cancel Continue You are now leaving www.bluebirdbio.com Links to sites outside of this website are provided as a resource to the |
HTTP Headers
HTTP/1.1 301 Moved Permanently Content-Length: 0 Content-Type: text/html; charset=UTF-8 Location: https://bluebirdbio.com/ Date: Wed, 20 Oct 2021 13:24:14 GMT HTTP/1.1 301 Moved Permanently Content-Length: 151 Content-Type: text/html; charset=UTF-8 Location: https://www.bluebirdbio.com/ Server: Microsoft-IIS/10.0 Strict-Transport-Security: max-age=31536000 Date: Wed, 20 Oct 2021 13:24:14 GMT HTTP/2 200 cache-control: no-cache, no-store pragma: no-cache content-length: 39822 content-type: text/html; charset=utf-8 expires: -1 server: Microsoft-IIS/10.0 set-cookie: ASP.NET_SessionId=id13o0wfj04g1i2pwnqgtqz2; path=/; HttpOnly; SameSite=Lax set-cookie: SC_ANALYTICS_GLOBAL_COOKIE=c682cc93248b4c6281b73cdaea4a15cf|False; expires=Sat, 18-Oct-2031 13:24:16 GMT; path=/; HttpOnly x-cache: PRIVATE_NOSTORE request-context: appId=cid-v1:15523070-15d8-4e08-8d91-6e50ced8d34a strict-transport-security: max-age=31536000 x-azure-ref-originshield: 0fxhwYQAAAADR5X0OoAyASIubg+UOvWpqRVdSMzBFREdFMDUxMwBjY2ZiMmIxYi1mMTYzLTQyYjQtYmEwNi0yNDE5MGIxZTNhMDk= x-azure-ref: 0fxhwYQAAAACjvHkDESe3RoNJw/Yy7LjTQ0hHRURHRTE2MTEAY2NmYjJiMWItZjE2My00MmI0LWJhMDYtMjQxOTBiMWUzYTA5 date: Wed, 20 Oct 2021 13:24:16 GMT |
bluebirdbio.com Whois Information
Domain Name: BLUEBIRDBIO.COM Registry Domain ID: 1607548031_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.comlaude.com Registrar URL: http://www.comlaude.com Updated Date: 2021-06-21T23:02:09Z Creation Date: 2010-07-21T17:58:27Z Registry Expiry Date: 2022-07-21T17:58:27Z Registrar: Nom-iq Ltd. dba COM LAUDE Registrar IANA ID: 470 Registrar Abuse Contact Email: abuse@comlaude.com Registrar Abuse Contact Phone: +442074218250 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NSGBR.COMLAUDE.CO.UK Name Server: NSSUI.COMLAUDE.CH Name Server: NSUSA.COMLAUDE.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-09T02:43:55Z <<< |